Venous Thromboembolism with Combined Oral Contraceptives Based on Estrogen and Progestin Content: A disproportionality analysis of the United States Food and Drug Administration Adverse Event Reportin
5 days ago
- #estrogen
- #oral contraceptives
- #venous thromboembolism
- Study compares venous thromboembolism (VTE) risk among different combined oral contraceptives (COCs) using FDA Adverse Event Reporting System data.
- Body-identical estrogen COCs (estetrol/drospirenone and E2V/dienogest) showed lower VTE reporting rates compared to ethinyl estradiol (EE)-based COCs.
- EE/drospirenone had the highest Proportional Reporting Ratio (PRR) for VTE, indicating higher risk.
- Progestin-only pills (drospirenone and norethindrone) showed similar lower PRRs to body-identical estrogen COCs.
- Findings suggest body-identical estrogen COCs may have a safer thrombotic profile than EE-based COCs.